Butyrate salts for use in inflammatory diseases

Abstract

This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inflammation. Preparations comprising a butyrate salt for enteral administration were found useful in the treatment of osteoarthritis, arteriosclerosis, rheumatism, psoriasis, multiple sclerosis, Alzheimer's' disease, Parkinson's disease, migraine, autism, depression, impaired kidney functioning, idiopathic subfertility, recurrent abortion, recurrent implantation failure, hangovers, and gout.

1 . A preparation comprising a butyrate salt for oral administration wherein the preparation is for use in the treatment of a subject suffering from a disease which is associated with systemic inflammation, wherein the disease is selected from the group consisting of osteoarthritis, Parkinson's disease, migraine, idiopathic subfertility, hangover and gout, and wherein the preparation comprises butyrate salt in a gastro-resistant formulation. 
     
     
         2 . (canceled) 
     
     
         3 . A preparation according to  claim 1 , wherein the gastro-resistant formulation is configured to release butyrate in the intestinal tract, preferably in an extended way along the entire length of the intestinal tract. 
     
     
         4 . (canceled) 
     
     
         5 . A preparation according to  claim 1 , wherein the use comprises a daily intake of at most 4 grams of butyrate. 
     
     
         6 . A preparation according to  claim 1 , wherein the butyrate salt is calcium butyrate. 
     
     
         7 . A preparation according to  claim 1 , wherein the gastro-resistant formulation comprises a triglyceride matrix. 
     
     
         8 . A preparation according to  claim 7 , wherein said triglyceride matrix comprises hardened palm oil. 
     
     
         9 . A preparation according to  claim 1 , wherein the gastro-resistant formulation comprises about 50% (w/w) calcium butyrate, and about 50% (w/w) hardened palm oil, or about 93% (w/w) calcium butyrate, and about 7% (w/w) hardened palm oil. 
     
     
         10 . A preparation according to  claim 1 , wherein the gastro-resistant formulation is in the form of a granulate, wherein the granulate comprises butyrate salt granules of 0.5-1.5 mm. 
     
     
         11 . A kit comprising a combination of a gastro-resistant formulation for oral administration according to  claim 1 , and a preparation comprising a butyrate salt in the form of a suppository for insertion in the rectum. 
     
     
         12 . A preparation according to  claim 3 , wherein the use comprises a daily intake of at most 4 grams of butyrate. 
     
     
         13 . A preparation according to  claim 3 , wherein the butyrate salt is calcium butyrate. 
     
     
         14 . A preparation according to  claim 5 , wherein the butyrate salt is calcium butyrate. 
     
     
         15 . A preparation according to  claim 3 , wherein the gastro-resistant formulation comprises a triglyceride matrix. 
     
     
         16 . A preparation according to  claim 5 , wherein the gastro-resistant formulation comprises a triglyceride matrix. 
     
     
         17 . A preparation according to  claim 3 , wherein said triglyceride matrix comprises hardened palm oil. 
     
     
         18 . A preparation according to  claim 5 , wherein said triglyceride matrix comprises hardened palm oil. 
     
     
         19 . A preparation according to  claim 3 , wherein the gastro-resistant formulation comprises about 50% (w/w) calcium butyrate, and about 50% (w/w) hardened palm oil, or about 93% (w/w) calcium butyrate, and about 7% (w/w) hardened palm oil. 
     
     
         20 . A preparation according to  claim 3 , wherein the gastro-resistant formulation is in the form of a granulate, wherein the granulate comprises butyrate salt granules of 0.5-1.5 mm.